Timepoint | Â | Â | Study period | ||||||
---|---|---|---|---|---|---|---|---|---|
Enrolment | Baseline | Injection 1 | Injection 2 | Injection 3 | Post-allocation | Close-out | |||
-t1 | Â | 0 | 1w | 2w | 2Â m | 6Â m | 9Â m | 12Â m | |
Enrolment: | |||||||||
 Eligibility screen | X |  |  |  |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |  |  |  |
 Allocation |  | X |  |  |  |  |  |  |  |
Interventions: | |||||||||
 Platelet rich plasma |  |  | X | X | X |  |  |  |  |
 Saline |  |  | X | X | X |  |  |  |  |
Assessments: | |||||||||
 Primary outcomes | |||||||||
  Average overall knee pain severity |  | X |  |  |  | X | X | X | X |
  Medial tibial cartilage volume |  | X |  |  |  |  |  |  | X |
 Secondary outcomes | |||||||||
  Walking pain severity |  | X |  |  |  | X |  |  | X |
  KOOS |  | X |  |  |  |  |  |  |  |
  ICOAP |  | X |  |  |  |  |  |  |  |
  Participant global ratings of change |  |  |  |  |  | X |  |  | X |
  AQoL-8D |  | X |  |  |  | X | X | X | X |
  MOAKS sub-scores |  | X |  |  |  |  |  |  | X |
  BML and cartilage defects score |  | X |  |  |  |  |  |  | X |
 Other measures | |||||||||
  Drug/supplement use |  | X |  |  |  | X |  |  | X |
  Cytokines and growth factors |  |  | X | X | X |  |  |  |  |
  Number of injections |  |  | X | X | X |  |  |  |  |
  Adverse events, co-interventions |  |  |  |  |  | X |  |  | X |
  Success of blinding |  |  |  |  | X |  |  |  |  |
 Descriptive measures | |||||||||
  Weight, height, BMI |  | X |  |  |  |  |  |  | X |
  Age, gender, symptom duration, x-ray severity, knee alignment, employment, symptom laterality, other symptoms, treatment expectation, PainDETECT, PASE, knee effusion |  | X |  |  |  |  |  |  |  |
 Health economic data | |||||||||
  QALYs, cost-effectiveness ratio, WHOHPQ |  | X |  |  |  | X | X | X | X |